Lasting Benefit With Nivo Plus Ipi in Advanced Liver Cancer Lasting Benefit With Nivo Plus Ipi in Advanced Liver Cancer

Long-term follow-up data show a continued benefit in advanced hepatocellular carcinoma (HCC) with nivolumab and ipilimumab after disease progression on sorafenib in the Checkmate 040 trial.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news